Trium Capital LLP's Schedule 13G Filing for Mural Oncology plc

Trium Capital LLP has filed a Schedule 13G with the SEC, disclosing its ownership of 1,760,097 ordinary shares of Mural Oncology plc, representing approximately 10.16% of the company's outstanding shares. The filing indicates that Trium Capital LLP has sole voting and dispositive power over these shares. The shares were acquired and are held in the ordinary course of business, with no intent to influence the control of Mural Oncology plc. The filing was made under Rule 13d-1(b) and was signed by Fredrik Ostlund, Chief Compliance Officer of Trium Capital LLP, on September 2, 2025. Mural Oncology plc is headquartered in Dublin, Ireland.